Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus epacadostat with chemotherapy versus EXTREME regimen in first-line recurrent or metastatic SCCHN
2017-003305-18Phase 3Terminated
- Sponsor
- Incyte
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of nivolumab and epacadostat in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Incyte. Primary endpoints: Progression-free survival and Overall survival. Started Mar 2018; status: terminated.
02
Drugs
nivolumabepacadostat
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2017-003305-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003305-18.